Can Pfizer Stock Double Your Money in 3 Years?
Pfizer (NYSE: PFE) has been a losing play for investors over the past 12 months. To wit: The drugmaker's stock has fallen by a whopping 28.8% over this period. Part of that decline has been driven by the anticipated drops in sales for its COVID-19 vaccine Comirnaty and the antiviral treatment Paxlovid. However, an underappreciated issue is that investors haven't been viewing Pfizer as a so-called "oasis stock."
Since the start of 2023, investors have shown a magnetic attraction to a select group of companies such as Eli Lilly (NYSE: LLY), Crispr Therapeutics, Microsoft, and Nvidia, causing their shares to dramatically outperform the broader market. The unifying theme across these high-performance stocks has been a connection to some form of exciting new technology like artificial intelligence, gene editing, or weight-loss treatments.
Source Fool.com
Pfizer Inc. Stock
With 28 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 41 € there is a positive potential of 44.21% for Pfizer Inc. compared to the current price of 28.43 €.
